Potentiation by the Hypoxic Cytotoxin SR 4233 of Cell Killing Produced by Fractionated Irradiation of Mouse Tumors

Cancer Research

Volumn 50, Issue 24, 1990, Pages 7745-7749

  Brown, J Martin ^a   Lemmon, Marilyn J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANIDAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GRAFT; CANCER RADIOTHERAPY; CELL KILLING; HYPOXIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES;

EID: 0025646401     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12:1239–1242,1986.
2. Baker, M. A., Zeman, E. M., Hirst, V. K., and Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res., 48:5947–5952, 1988.
3. Stratford, I. J., and Stephens, M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16:973–976,1989.
4. Zeman, E. M., Hirst, V. K., Lemmon, M. J., and Brown, J. M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol., 12:209–218,1988.
5. Brown, J. M., and Lemmon, M. J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., in press, 1990.
6. Brown, J. M. Exploitation of bioreductive agents with vasoactive drugs. In: E. M. Fielden, J. F. Fowler, J. H. Hendry, and D. Scott (eds.), Radiation Research, Proceedings of the 8th International Congress of Radiation Research, Vol. 2, pp. 719–724. London: Taylor and Francis, 1987.
7. Sun, J. R., and Brown, J. M. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res., 49:5664–5670,1989.
8. Laderoute, K., Wardman, P., and Rauth, A. M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-l,2,4-benzotriazine-l,4-dioxide (SR 4233). Biochem. Pharmacol., 37:1487–1495, 1988.
9. Zeman, E. M., and Brown, J. M. Pre-and post-irradiation radiosensitization by SR 4233. Int. J. Radiat. Oncol. Biol. Phys., 16:967–971,1989.
10. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol., 52:650–656, 1979.
11. Chaplin, D. J., Durand, R. E., and Olive, P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys., 12:1279–1282,1986.
12. Zeman, E. M., Lemmon, M. J., and Brown, J. M. Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int. J. Rad. Oncol. Biol. Phys., 18:125–132, 1990.
13. Brown, J. M., and Lemmon, M. J. SR 4233: A tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol., in press, 1990.
14. Hirst, D. G., Brown, J. M., and Hazlehurst, J. L. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of l-(2-chloroethyl)-3-cyclohexyl-l -nitrosourea. Cancer Res., 43:1961–1965,1983.
15. Rockwell, S. C., Kallman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst., 49:735–749, 1972.
16. Twentyman, P. R., Brown, J. M., Gray, J. W., Franko, A. J., Scoles, M. A., and Kallman, R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J. Natl. Cancer Inst., 64: 595–604,1980.
17. Siemann, D. W., and Keng, P. C. Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas, (ii) Cell sorting. Br. J. Cancer, 58: 296–300, 1988.
18. Moulder, J. E., and Rockwell, S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys., 10:695–712, 1984.
19. Brown, J. M., Twentyman, P. R., and Zamvil, S. S. Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J. Natl. Cancer Inst., 64:605–611, 1980.
20. Brown, J. M. Hypoxic cell radiosensitizers: where next? Int. J. Radiat. Oncol. Biol. Phys., 16:987–993, 1989.
21. Hill, R. P. Sensitizers and radiation dose fractionation: results and interpretations. Int. J. Radiat. Oncol. Biol. Phys., 12:1049–1054,1986.
22. Brown, J. M., and Yu, N. Y. Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 10:1207–1212, 1984.
23. Brown, J. M., and Koong, A. The therapeutic advantage of hypoxic cells in tumors: A theoretical study. J. Natl. Cancer Inst., in press, 1990.